{"transactions":[{"id":724987,"issuer":{"id":4208,"kind":"organization","name":"Celldex Therapeutics, Inc."},"owners":[{"id":35029,"kind":"person","name":"Crowley Elizabeth","position":1,"cik":"0001681854","reported_name":"Crowley Elizabeth","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SR. VP & CPDO"}}],"security":"Incentive Stock Option (right to buy)","published_at":"2026-06-29T20:17:10.000Z","date":"2026-06-25","kind":"grant","planned":false,"acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan."},{"field":"date","element":"transactionDate","label":"F1","text":"Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% vest on June 25, 2027 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters."}],"balance_after":100000,"derivative":{"exercise_price":34.09,"exercise_date":"2027-06-25","expiration_date":"2036-06-25","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001681854-26-000002","document":"form4-06292026_080604.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/744218/000168185426000002/form4-06292026_080604.xml","form_type":"4"}},{"id":1119016,"issuer":{"id":4208,"kind":"organization","name":"Celldex Therapeutics, Inc."},"owners":[{"id":35029,"kind":"person","name":"Crowley Elizabeth","position":1,"cik":"0001681854","reported_name":"Crowley Elizabeth","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SR. VP & CPDO"}}],"security":"Incentive Stock Option (right to buy)","published_at":"2025-06-09T20:22:10.000Z","date":"2025-06-05","kind":"grant","planned":false,"acquired":true,"shares":85000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan."},{"field":"date","element":"transactionDate","label":"F1","text":"Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% vest on June 5, 2026 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters."}],"balance_after":85000,"derivative":{"exercise_price":19.53,"exercise_date":"2026-06-05","expiration_date":"2035-06-05","underlying":"Common Stock","underlying_shares":85000},"source":{"system":"sec-edgar","filing":"0001415889-25-016257","document":"form4-06092025_080605.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/744218/000141588925016257/form4-06092025_080605.xml","form_type":"4"}},{"id":1476640,"issuer":{"id":4208,"kind":"organization","name":"Celldex Therapeutics, Inc."},"owners":[{"id":35029,"kind":"person","name":"Crowley Elizabeth","position":1,"cik":"0001681854","reported_name":"Crowley Elizabeth","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SR. VP & CPDO"}}],"security":"Incentive Stock Option (Right to Buy)","published_at":"2024-06-18T20:04:13.000Z","date":"2024-06-14","kind":"exercise","planned":false,"acquired":false,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"As of June 18, 2024, the option is fully vested."}],"balance_after":46500,"derivative":{"exercise_price":10.38,"expiration_date":"2030-06-18","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001415889-24-017362","document":"form4-06182024_080610.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/744218/000141588924017362/form4-06182024_080610.xml","form_type":"4"}},{"id":1476639,"issuer":{"id":4208,"kind":"organization","name":"Celldex Therapeutics, Inc."},"owners":[{"id":35029,"kind":"person","name":"Crowley Elizabeth","position":1,"cik":"0001681854","reported_name":"Crowley Elizabeth","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SR. VP & CPDO"}}],"security":"Common Stock","published_at":"2024-06-18T20:04:13.000Z","date":"2024-06-14","kind":"sale","planned":false,"acquired":false,"shares":30000,"price":34.8654,"value":1045962.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.51 to $35.39 per share, inclusive. The reporting person undertakes to provide to Celldex Therapeutics, Inc., any security holder of Celldex Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein."}],"balance_after":9074,"source":{"system":"sec-edgar","filing":"0001415889-24-017362","document":"form4-06182024_080610.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/744218/000141588924017362/form4-06182024_080610.xml","form_type":"4"}},{"id":1476638,"issuer":{"id":4208,"kind":"organization","name":"Celldex Therapeutics, Inc."},"owners":[{"id":35029,"kind":"person","name":"Crowley Elizabeth","position":1,"cik":"0001681854","reported_name":"Crowley Elizabeth","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SR. VP & CPDO"}}],"security":"Common Stock","published_at":"2024-06-18T20:04:13.000Z","date":"2024-06-14","kind":"exercise","planned":false,"acquired":true,"shares":30000,"price":10.38,"value":311400.0,"ownership":{"direct":true},"balance_after":39074,"source":{"system":"sec-edgar","filing":"0001415889-24-017362","document":"form4-06182024_080610.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/744218/000141588924017362/form4-06182024_080610.xml","form_type":"4"}},{"id":1478181,"issuer":{"id":4208,"kind":"organization","name":"Celldex Therapeutics, Inc."},"owners":[{"id":35029,"kind":"person","name":"Crowley Elizabeth","position":1,"cik":"0001681854","reported_name":"Crowley Elizabeth","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SR. VP & CPDO"}}],"security":"Incentive Stock Option (right to buy)","published_at":"2024-06-17T20:16:41.000Z","date":"2024-06-13","kind":"grant","planned":false,"acquired":true,"shares":85000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan."},{"field":"date","element":"transactionDate","label":"F1","text":"Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% vest on June 13, 2025 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters."}],"balance_after":85000,"derivative":{"exercise_price":36.43,"exercise_date":"2025-06-13","expiration_date":"2034-06-13","underlying":"Common Stock","underlying_shares":85000},"source":{"system":"sec-edgar","filing":"0001415889-24-017179","document":"form4-06172024_080638.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/744218/000141588924017179/form4-06172024_080638.xml","form_type":"4"}},{"id":1484272,"issuer":{"id":4208,"kind":"organization","name":"Celldex Therapeutics, Inc."},"owners":[{"id":35029,"kind":"person","name":"Crowley Elizabeth","position":1,"cik":"0001681854","reported_name":"Crowley Elizabeth","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SR. VP & CPDO"}}],"security":"Incentive Stock Option (Right to Buy)","published_at":"2024-06-11T20:02:57.000Z","date":"2024-06-07","kind":"exercise","planned":false,"acquired":false,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"As of June 13, 2022, the option is fully vested."}],"balance_after":0,"derivative":{"exercise_price":9.0165,"expiration_date":"2028-06-13","underlying":"Common Stock","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0001415889-24-016345","document":"form4-06112024_080653.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/744218/000141588924016345/form4-06112024_080653.xml","form_type":"4"}},{"id":1484271,"issuer":{"id":4208,"kind":"organization","name":"Celldex Therapeutics, Inc."},"owners":[{"id":35029,"kind":"person","name":"Crowley Elizabeth","position":1,"cik":"0001681854","reported_name":"Crowley Elizabeth","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SR. VP & CPDO"}}],"security":"Incentive Stock Option (Right to Buy)","published_at":"2024-06-11T20:02:57.000Z","date":"2024-06-07","kind":"exercise","planned":false,"acquired":false,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% vested on June 18, 2021 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters."}],"balance_after":76500,"derivative":{"exercise_price":10.38,"expiration_date":"2030-06-18","underlying":"Common Stock","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0001415889-24-016345","document":"form4-06112024_080653.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/744218/000141588924016345/form4-06112024_080653.xml","form_type":"4"}},{"id":1484270,"issuer":{"id":4208,"kind":"organization","name":"Celldex Therapeutics, Inc."},"owners":[{"id":35029,"kind":"person","name":"Crowley Elizabeth","position":1,"cik":"0001681854","reported_name":"Crowley Elizabeth","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SR. VP & CPDO"}}],"security":"Common Stock","published_at":"2024-06-11T20:02:57.000Z","date":"2024-06-07","kind":"sale","planned":false,"acquired":false,"shares":15000,"price":35.0582,"value":525873.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.86 to $35.59 per share, inclusive. The reporting person undertakes to provide to Celldex Therapeutics, Inc., any security holder of Celldex Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein."}],"balance_after":9074,"source":{"system":"sec-edgar","filing":"0001415889-24-016345","document":"form4-06112024_080653.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/744218/000141588924016345/form4-06112024_080653.xml","form_type":"4"}},{"id":1484269,"issuer":{"id":4208,"kind":"organization","name":"Celldex Therapeutics, Inc."},"owners":[{"id":35029,"kind":"person","name":"Crowley Elizabeth","position":1,"cik":"0001681854","reported_name":"Crowley Elizabeth","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SR. VP & CPDO"}}],"security":"Common Stock","published_at":"2024-06-11T20:02:57.000Z","date":"2024-06-07","kind":"exercise","planned":false,"acquired":true,"shares":7500,"price":9.0165,"value":67623.75,"ownership":{"direct":true},"balance_after":24074,"source":{"system":"sec-edgar","filing":"0001415889-24-016345","document":"form4-06112024_080653.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/744218/000141588924016345/form4-06112024_080653.xml","form_type":"4"}},{"id":1484268,"issuer":{"id":4208,"kind":"organization","name":"Celldex Therapeutics, Inc."},"owners":[{"id":35029,"kind":"person","name":"Crowley Elizabeth","position":1,"cik":"0001681854","reported_name":"Crowley Elizabeth","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SR. VP & CPDO"}}],"security":"Common Stock","published_at":"2024-06-11T20:02:57.000Z","date":"2024-06-07","kind":"exercise","planned":false,"acquired":true,"shares":7500,"price":10.38,"value":77850.0,"ownership":{"direct":true},"balance_after":16574,"source":{"system":"sec-edgar","filing":"0001415889-24-016345","document":"form4-06112024_080653.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/744218/000141588924016345/form4-06112024_080653.xml","form_type":"4"}},{"id":1496014,"issuer":{"id":4208,"kind":"organization","name":"Celldex Therapeutics, Inc."},"owners":[{"id":35029,"kind":"person","name":"Crowley Elizabeth","position":1,"cik":"0001681854","reported_name":"Crowley Elizabeth","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SR. VP & CPDO"}}],"security":"Incentive Stock Option (Right to Buy)","published_at":"2024-06-03T20:04:08.000Z","date":"2024-05-30","kind":"exercise","planned":false,"acquired":false,"shares":8500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"As of June 13, 2022, the option is fully vested."}],"balance_after":7500,"derivative":{"exercise_price":9.0165,"expiration_date":"2028-06-13","underlying":"Common Stock","underlying_shares":8500},"source":{"system":"sec-edgar","filing":"0001415889-24-015137","document":"form4-06032024_080604.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/744218/000141588924015137/form4-06032024_080604.xml","form_type":"4"}},{"id":1496013,"issuer":{"id":4208,"kind":"organization","name":"Celldex Therapeutics, Inc."},"owners":[{"id":35029,"kind":"person","name":"Crowley Elizabeth","position":1,"cik":"0001681854","reported_name":"Crowley Elizabeth","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SR. VP & CPDO"}}],"security":"Incentive Stock Option (Right to Buy)","published_at":"2024-06-03T20:04:08.000Z","date":"2024-05-30","kind":"exercise","planned":false,"acquired":false,"shares":34445,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"As of June 19, 2023, the option is fully vested."}],"balance_after":0,"derivative":{"exercise_price":2.78,"expiration_date":"2029-06-19","underlying":"Common Stock","underlying_shares":34445},"source":{"system":"sec-edgar","filing":"0001415889-24-015137","document":"form4-06032024_080604.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/744218/000141588924015137/form4-06032024_080604.xml","form_type":"4"}},{"id":1496012,"issuer":{"id":4208,"kind":"organization","name":"Celldex Therapeutics, Inc."},"owners":[{"id":35029,"kind":"person","name":"Crowley Elizabeth","position":1,"cik":"0001681854","reported_name":"Crowley Elizabeth","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SR. VP & CPDO"}}],"security":"Common Stock","published_at":"2024-06-03T20:04:08.000Z","date":"2024-05-30","kind":"sale","planned":false,"acquired":false,"shares":38597,"price":33.6395,"value":1298383.7815,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.39 to $33.8934 per share, inclusive. The reporting person undertakes to provide to Celldex Therapeutics, Inc., any security holder of Celldex Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein."},{"field":"shares","element":"transactionShares","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.39 to $33.8934 per share, inclusive. The reporting person undertakes to provide to Celldex Therapeutics, Inc., any security holder of Celldex Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.39 to $33.8934 per share, inclusive. The reporting person undertakes to provide to Celldex Therapeutics, Inc., any security holder of Celldex Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein."}],"balance_after":9074,"source":{"system":"sec-edgar","filing":"0001415889-24-015137","document":"form4-06032024_080604.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/744218/000141588924015137/form4-06032024_080604.xml","form_type":"4"}},{"id":1496011,"issuer":{"id":4208,"kind":"organization","name":"Celldex Therapeutics, Inc."},"owners":[{"id":35029,"kind":"person","name":"Crowley Elizabeth","position":1,"cik":"0001681854","reported_name":"Crowley Elizabeth","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SR. VP & CPDO"}}],"security":"Common Stock","published_at":"2024-06-03T20:04:08.000Z","date":"2024-05-30","kind":"exercise","planned":false,"acquired":true,"shares":8500,"price":9.0165,"value":76640.25,"ownership":{"direct":true},"balance_after":47671,"source":{"system":"sec-edgar","filing":"0001415889-24-015137","document":"form4-06032024_080604.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/744218/000141588924015137/form4-06032024_080604.xml","form_type":"4"}},{"id":1496010,"issuer":{"id":4208,"kind":"organization","name":"Celldex Therapeutics, Inc."},"owners":[{"id":35029,"kind":"person","name":"Crowley Elizabeth","position":1,"cik":"0001681854","reported_name":"Crowley Elizabeth","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SR. VP & CPDO"}}],"security":"Common Stock","published_at":"2024-06-03T20:04:08.000Z","date":"2024-05-30","kind":"exercise","planned":false,"acquired":true,"shares":34445,"price":2.78,"value":95757.1,"ownership":{"direct":true},"balance_after":39171,"source":{"system":"sec-edgar","filing":"0001415889-24-015137","document":"form4-06032024_080604.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/744218/000141588924015137/form4-06032024_080604.xml","form_type":"4"}},{"id":1850849,"issuer":{"id":4208,"kind":"organization","name":"Celldex Therapeutics, Inc."},"owners":[{"id":35029,"kind":"person","name":"Crowley Elizabeth","position":1,"cik":"0001681854","reported_name":"Crowley Elizabeth","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SR. VP &CPDO"}}],"security":"Incentive Stock Option (right to buy)","published_at":"2023-06-20T20:16:07.000Z","date":"2023-06-15","kind":"grant","planned":false,"acquired":true,"shares":80000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan."},{"field":"date","element":"transactionDate","label":"F1","text":"Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% vest on June 15, 2024 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters."}],"balance_after":80000,"derivative":{"exercise_price":36.87,"exercise_date":"2024-06-15","expiration_date":"2033-06-15","underlying":"Common Stock","underlying_shares":80000},"source":{"system":"sec-edgar","filing":"0001415889-23-010043","document":"form4-06202023_080649.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/744218/000141588923010043/form4-06202023_080649.xml","form_type":"4"}},{"id":2229180,"issuer":{"id":4208,"kind":"organization","name":"Celldex Therapeutics, Inc."},"owners":[{"id":35029,"kind":"person","name":"Crowley Elizabeth","position":1,"cik":"0001681854","reported_name":"Crowley Elizabeth","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SR. VP &CPDO"}}],"security":"Incentive Stock Option (right to buy)","published_at":"2022-06-17T20:14:36.000Z","date":"2022-06-16","kind":"grant","acquired":true,"shares":77000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan."},{"field":"date","element":"transactionDate","label":"F1","text":"Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% vest on June 16, 2023 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters."}],"balance_after":77000,"derivative":{"exercise_price":22.48,"exercise_date":"2023-06-16","expiration_date":"2032-06-16","underlying":"Common Stock","underlying_shares":77000},"source":{"system":"sec-edgar","filing":"0001415889-22-006722","document":"form4-06172022_010627.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/744218/000141588922006722/form4-06172022_010627.xml","form_type":"4"}},{"id":2478277,"issuer":{"id":4208,"kind":"organization","name":"Celldex Therapeutics, Inc."},"owners":[{"id":35029,"kind":"person","name":"Crowley Elizabeth","position":1,"cik":"0001681854","reported_name":"Crowley Elizabeth","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP &CPDO"}}],"security":"Incentive Stock Option (Right to Buy)","published_at":"2021-12-10T21:02:59.000Z","date":"2021-12-08","kind":"exercise","acquired":false,"shares":4000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On February 8, 2019, Celldex Therapeutics, Inc. effected a 1-for-15 reverse stock split of its common stock (the \"Reverse Stock Split\"). This option was previously reported as covering 300,000 shares at an exercise price of $0.6011 per share, but has been adjusted to reflect the Reverse Stock Split."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"25% vested on June 13, 2019 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"On February 8, 2019, Celldex Therapeutics, Inc. effected a 1-for-15 reverse stock split of its common stock (the \"Reverse Stock Split\"). This option was previously reported as covering 300,000 shares at an exercise price of $0.6011 per share, but has been adjusted to reflect the Reverse Stock Split."}],"balance_after":16000,"derivative":{"exercise_price":9.0165,"expiration_date":"2028-06-13","underlying":"Common Stock","underlying_shares":4000},"source":{"system":"sec-edgar","filing":"0001179110-21-010819","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/744218/000117911021010819/edgar.xml","form_type":"4"}},{"id":2478276,"issuer":{"id":4208,"kind":"organization","name":"Celldex Therapeutics, Inc."},"owners":[{"id":35029,"kind":"person","name":"Crowley Elizabeth","position":1,"cik":"0001681854","reported_name":"Crowley Elizabeth","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP &CPDO"}}],"security":"Common Stock","published_at":"2021-12-10T21:02:59.000Z","date":"2021-12-08","kind":"sale","acquired":false,"shares":4000,"price":40,"value":160000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sale of the shares of Common Stock were made pursuant to a plan intended to comply with Rule 10b5-1 of the Exchange Act, previously entered into on September 15, 2021."},{"field":"shares","element":"transactionShares","label":"F2","text":"The sale of the shares of Common Stock were made pursuant to a plan intended to comply with Rule 10b5-1 of the Exchange Act, previously entered into on September 15, 2021."}],"balance_after":4726,"source":{"system":"sec-edgar","filing":"0001179110-21-010819","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/744218/000117911021010819/edgar.xml","form_type":"4"}},{"id":2478275,"issuer":{"id":4208,"kind":"organization","name":"Celldex Therapeutics, Inc."},"owners":[{"id":35029,"kind":"person","name":"Crowley Elizabeth","position":1,"cik":"0001681854","reported_name":"Crowley Elizabeth","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP &CPDO"}}],"security":"Common Stock","published_at":"2021-12-10T21:02:59.000Z","date":"2021-12-08","kind":"exercise","acquired":true,"shares":4000,"price":9.0165,"value":36066.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On February 8, 2019, Celldex Therapeutics, Inc. effected a 1-for-15 reverse stock split of its common stock (the \"Reverse Stock Split\"). This option was previously reported as covering 300,000 shares at an exercise price of $0.6011 per share, but has been adjusted to reflect the Reverse Stock Split."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On February 8, 2019, Celldex Therapeutics, Inc. effected a 1-for-15 reverse stock split of its common stock (the \"Reverse Stock Split\"). This option was previously reported as covering 300,000 shares at an exercise price of $0.6011 per share, but has been adjusted to reflect the Reverse Stock Split."}],"balance_after":8726,"source":{"system":"sec-edgar","filing":"0001179110-21-010819","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/744218/000117911021010819/edgar.xml","form_type":"4"}},{"id":2527767,"issuer":{"id":4208,"kind":"organization","name":"Celldex Therapeutics, Inc."},"owners":[{"id":35029,"kind":"person","name":"Crowley Elizabeth","position":1,"cik":"0001681854","reported_name":"Crowley Elizabeth","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP &CPDO"}}],"security":"Incentive Stock Option (Right to Buy)","published_at":"2021-11-03T20:02:35.000Z","date":"2021-11-01","kind":"exercise","acquired":false,"shares":8555,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"25% vested on June 19, 2020 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters."}],"balance_after":34445,"derivative":{"exercise_price":2.78,"expiration_date":"2029-06-19","underlying":"Common Stock","underlying_shares":8555},"source":{"system":"sec-edgar","filing":"0001179110-21-009816","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/744218/000117911021009816/edgar.xml","form_type":"4"}},{"id":2527766,"issuer":{"id":4208,"kind":"organization","name":"Celldex Therapeutics, Inc."},"owners":[{"id":35029,"kind":"person","name":"Crowley Elizabeth","position":1,"cik":"0001681854","reported_name":"Crowley Elizabeth","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP &CPDO"}}],"security":"Common Stock","published_at":"2021-11-03T20:02:35.000Z","date":"2021-11-01","kind":"sale","acquired":false,"shares":1189,"price":41.616,"value":49481.424,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On February 8, 2019, Celldex Therapeutics, Inc. effected a 1-for-15 reverse stock split of its common stock (the \"Reverse Stock Split\"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split."},{"field":"shares","element":"transactionShares","label":"F2","text":"The sale of the shares of Common Stock were made pursuant to a plan intended to comply with Rule 10b5-1 of the Exchange Act, previously entered into on September 15, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.400 to $41.990 per share, inclusive. The reporting person undertakes to provide to Celldex Therapeutics, Inc., any security holder of Celldex Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein."}],"balance_after":4726,"source":{"system":"sec-edgar","filing":"0001179110-21-009816","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/744218/000117911021009816/edgar.xml","form_type":"4"}},{"id":2527765,"issuer":{"id":4208,"kind":"organization","name":"Celldex Therapeutics, Inc."},"owners":[{"id":35029,"kind":"person","name":"Crowley Elizabeth","position":1,"cik":"0001681854","reported_name":"Crowley Elizabeth","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP &CPDO"}}],"security":"Common Stock","published_at":"2021-11-03T20:02:35.000Z","date":"2021-11-01","kind":"sale","acquired":false,"shares":600,"price":43.113,"value":25867.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On February 8, 2019, Celldex Therapeutics, Inc. effected a 1-for-15 reverse stock split of its common stock (the \"Reverse Stock Split\"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split."},{"field":"shares","element":"transactionShares","label":"F2","text":"The sale of the shares of Common Stock were made pursuant to a plan intended to comply with Rule 10b5-1 of the Exchange Act, previously entered into on September 15, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.580 to $43.360 per share, inclusive. The reporting person undertakes to provide to Celldex Therapeutics, Inc., any security holder of Celldex Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein."}],"balance_after":5915,"source":{"system":"sec-edgar","filing":"0001179110-21-009816","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/744218/000117911021009816/edgar.xml","form_type":"4"}},{"id":2527764,"issuer":{"id":4208,"kind":"organization","name":"Celldex Therapeutics, Inc."},"owners":[{"id":35029,"kind":"person","name":"Crowley Elizabeth","position":1,"cik":"0001681854","reported_name":"Crowley Elizabeth","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP &CPDO"}}],"security":"Common Stock","published_at":"2021-11-03T20:02:35.000Z","date":"2021-11-01","kind":"sale","acquired":false,"shares":2528,"price":44.116,"value":111525.248,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On February 8, 2019, Celldex Therapeutics, Inc. effected a 1-for-15 reverse stock split of its common stock (the \"Reverse Stock Split\"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split."},{"field":"shares","element":"transactionShares","label":"F2","text":"The sale of the shares of Common Stock were made pursuant to a plan intended to comply with Rule 10b5-1 of the Exchange Act, previously entered into on September 15, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.710 to $44.420 per share, inclusive. The reporting person undertakes to provide to Celldex Therapeutics, Inc., any security holder of Celldex Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein."}],"balance_after":6515,"source":{"system":"sec-edgar","filing":"0001179110-21-009816","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/744218/000117911021009816/edgar.xml","form_type":"4"}},{"id":2527763,"issuer":{"id":4208,"kind":"organization","name":"Celldex Therapeutics, Inc."},"owners":[{"id":35029,"kind":"person","name":"Crowley Elizabeth","position":1,"cik":"0001681854","reported_name":"Crowley Elizabeth","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP &CPDO"}}],"security":"Common Stock","published_at":"2021-11-03T20:02:35.000Z","date":"2021-11-01","kind":"exercise","acquired":true,"shares":8555,"price":2.78,"value":23782.9,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"On February 8, 2019, Celldex Therapeutics, Inc. effected a 1-for-15 reverse stock split of its common stock (the \"Reverse Stock Split\"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split."}],"balance_after":9043,"source":{"system":"sec-edgar","filing":"0001179110-21-009816","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/744218/000117911021009816/edgar.xml","form_type":"4"}},{"id":2662449,"issuer":{"id":4208,"kind":"organization","name":"Celldex Therapeutics, Inc."},"owners":[{"id":35029,"kind":"person","name":"Crowley Elizabeth","position":1,"cik":"0001681854","reported_name":"Crowley Elizabeth","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP &CPDO"}}],"security":"Incentive Stock Option (right to buy)","published_at":"2021-06-21T20:27:36.000Z","date":"2021-06-17","kind":"grant","acquired":true,"shares":58000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% vest on June 17, 2022 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters."}],"balance_after":58000,"derivative":{"exercise_price":28,"exercise_date":"2022-06-17","expiration_date":"2031-06-17","underlying":"Common Stock","underlying_shares":58000},"source":{"system":"sec-edgar","filing":"0001179110-21-006906","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/744218/000117911021006906/edgar.xml","form_type":"4"}},{"id":3104884,"issuer":{"id":4208,"kind":"organization","name":"Celldex Therapeutics, Inc."},"owners":[{"id":35029,"kind":"person","name":"Crowley Elizabeth","position":1,"cik":"0001681854","reported_name":"Crowley Elizabeth","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP &CPDO"}}],"security":"Incentive Stock Option (right to buy)","published_at":"2020-06-19T12:06:30.000Z","date":"2020-06-18","kind":"grant","acquired":true,"shares":84000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents option granted by the Issuer pursuant to its 2008 Stock Option and Incentive Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% vest on June 18, 2021 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters."}],"balance_after":84000,"derivative":{"exercise_price":10.38,"exercise_date":"2021-06-18","expiration_date":"2030-06-18","underlying":"Common Stock","underlying_shares":84000},"source":{"system":"sec-edgar","filing":"0001179110-20-007595","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/744218/000117911020007595/edgar.xml","form_type":"4"}},{"id":3483579,"issuer":{"id":4208,"kind":"organization","name":"Celldex Therapeutics, Inc."},"owners":[{"id":35029,"kind":"person","name":"Crowley Elizabeth","position":1,"cik":"0001681854","reported_name":"Crowley Elizabeth","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP &CPDO"}}],"security":"Incentive Stock Option (right to buy)","published_at":"2019-06-20T20:28:35.000Z","date":"2019-06-19","kind":"grant","acquired":true,"shares":43000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents option granted by the Issuer pursuant to its 2008 Stock Option and Incentive Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% vest on June 19, 2020 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters."}],"balance_after":43000,"derivative":{"exercise_price":2.78,"exercise_date":"2020-06-19","expiration_date":"2029-06-19","underlying":"Common Stock","underlying_shares":43000},"source":{"system":"sec-edgar","filing":"0001179110-19-007976","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/744218/000117911019007976/edgar.xml","form_type":"4"}},{"id":3893272,"issuer":{"id":4208,"kind":"organization","name":"Celldex Therapeutics, Inc."},"owners":[{"id":35029,"kind":"person","name":"Crowley Elizabeth","position":1,"cik":"0001681854","reported_name":"Crowley Elizabeth","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP &CPDO"}}],"security":"Incentive Stock Option (right to buy)","published_at":"2018-06-15T11:48:22.000Z","date":"2018-06-13","kind":"grant","acquired":true,"shares":300000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents option granted by the Issuer pursuant to its 2008 Stock Option and Incentive Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% vest on June 13, 2019 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters."}],"balance_after":300000,"derivative":{"exercise_price":0.6011,"exercise_date":"2019-06-13","expiration_date":"2028-06-13","underlying":"Common Stock","underlying_shares":300000},"source":{"system":"sec-edgar","filing":"0001179110-18-008567","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/744218/000117911018008567/edgar.xml","form_type":"4"}},{"id":4280094,"issuer":{"id":4208,"kind":"organization","name":"Celldex Therapeutics, Inc."},"owners":[{"id":35029,"kind":"person","name":"Crowley Elizabeth","position":1,"cik":"0001681854","reported_name":"Crowley Elizabeth","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP &CPDO"}}],"security":"Incentive Stock Option (right to buy)","published_at":"2017-06-16T13:27:32.000Z","date":"2017-06-15","kind":"grant","acquired":true,"shares":82000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents option granted by the Issuer pursuant to its 2008 Stock Option and Incentive Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% vest on June 15, 2018 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters."}],"balance_after":82000,"derivative":{"exercise_price":2.32,"exercise_date":"2018-06-15","expiration_date":"2027-06-15","underlying":"Common Stock","underlying_shares":82000},"source":{"system":"sec-edgar","filing":"0001179110-17-009156","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/744218/000117911017009156/edgar.xml","form_type":"4"}}]}